The relation between HCP and Pharma A stakeholders debate

Transcription

1 BeAPP Medical Department Day The relation between HCP and Pharma A stakeholders debate Professor Cedric HERMANS

2 Speaker disclosures Shareholder Grant / Research Support Consultant Employee Paid Instructor Speaker bureau Other No relevant conflicts of interest to declare Pfizer, Bayer, Shire, Novo Nordisk Pfizer, Bayer, Shire, Novo Nordisk, CSL Behring, Octapharma, Sobi, LFB, CAF-CDF, OctaPharma No relevant conflicts of interest to declare No relevant conflicts of interest to declare No relevant conflicts of interest to declare Disclaimer : content of these slides represents personal views/perceptions of C. HERMANS

3 Prof. C Hermans, MD, PhD, FRCP (Lon, Edin) Full Professor (UCL) Adjunct Head Division Haematology (UCL-St-Luc), Director Haemostasis and Thrombosis Unit / Haemophilia Centre Vice-Dean School of Medicine UCL Chief Editor / Louvain Médical President of EAHAD (European Association Haemophilia and Allied Disorders) Manager LVHC Consulting SNC

4 Personal interactions with the industry National and international advisory boards (Lufthansa Gold Card renewed 12/2016) Steering committee (international meetings) Strategic boards / meetings Internal educational programs Consultancy Preceptorship Speaker bureau Investigator in studies Development of educational material

5 Medical «status» General practictioner Specialist University hospital specialist Key opinion leader (KOL) Interaction(s) with the industry Information, prescription support Information, prescription support,. Information (early development, pipeline), advising, investigator in clinical studies, speaker bureau at national or international levels

6 Personal experience with Pharma Industry as a whole Positive Access to information, education International networking through adboards, speakers bureau Visibility Funding Publication Research opportunities (PI), job opportunities Negative Conflict of interest, loss of independence, external pressure, image of «corrupted» physician Rigidity, internal regulatory issues, Time pressure Inappropriate financial compensation / fair value Risk of utilization Interference with patients management

7 Impact of Pharma on Health Care Professionals, perceptions Highly dependent on status : GP / specialist / KOL Influenced by personal - subjective parameters / personal behaviour Close collaboration / partnership > < Refractory Many opportunities of collaboration in Belgium compared to other geographical areas

8 View on evolution in relationship (last 10 years) Decreasing influence of hospital physicians on formulary hospital No recreational activities only «clean» activities Strict control of all expenditures Less time among doctors to be dedicated to contacts with pharma Perception of richer companies > < poorer hospitals / diversion of public heath money from physicians/hospitals to Pharma Each minute devoted to contact with pharma should have an added value

9 View on future look Promotion of added-value of each contact with physicians New areas of collaborations Stability / sustainability of pharma representatives New partnerships

10 MSL/Field Med Managers versus Sales interactions, complementarity, experiences Sales interactions : physicians less involved MSL / Medical Science Liaison Real expertise Added value High scientific profile Scientific support : transparent, neutral, high-quality

11 What is a good collaboration, what s not Good collaboration Mutually beneficial Transparent Long-term Added-value for both partners

12 Type of interactions: role of digital, new media? AdBoards? Point of view? Type of interactions Digital / new media : difficult to anticipate Adboard : great value if well organised for KOL or other HP

13 Disclosure and transparency How do you live it? Transparence is absolutely needed Each support / each compensation should be carefully justified